Search
Now showing items 1-1 of 1
Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma.
(AMER ASSOC CANCER RESEARCH, 2023-02-01)
Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, ...